Caliway Biopharmaceuticals unveiled the impressive results of its second Phase 2b clinical study (CBL-0205) for CBL-514, the world’s first investigational drug for large-area localized fat reduction.

Conducted across 15 sites in the U.S. and Canada, the study met all primary and critical secondary endpoints, showcasing CBL-514’s significant efficacy and safety. Notably, 54.2% of participants in the treatment group achieved at least a 20% reduction in fat volume within four weeks post-treatment.

With the successful completion of all Phase 2 trials, Caliway is poised to advance to pivotal global Phase 3 studies, targeting the second half of 2025, to redefine localized fat reduction in aesthetic medicine.